

**PIERRE-YVES CREMIEUX, PH.D.**  
**President**

Office: 617 425 8135  
Fax: 617 425 8001  
pierre.cremieux@analysisgroup.com

111 Huntington Avenue  
14th Floor  
Boston, MA 02199

Pierre-Yves Cremieux, President of Analysis Group, has a broad range of expertise in health economics, antitrust, statistics, and labor economics. He has consulted to numerous clients in the United States and Canada and testified in bench and jury trials, arbitrations, and administrative proceedings.

Dr. Cremieux has served as an expert and supported other experts in both litigation and non-litigation matters on antitrust issues; general commercial claims; contractual disputes; and a number of labor-related matters in a variety of industries, including high tech, pharmaceuticals, biotech, financial products, consumer products, and commodities. He has assessed the evaluation of damages on a class-wide basis in some of the largest class action matters in recent years.

His scientific research in antitrust economics, class certification, health economics, and statistics has been published in numerous peer-reviewed journals, including the *George Mason Law Review*, the *American Bar Association Economics Committee Newsletter*, *The Review of Economics and Statistics*, the *Journal of Health Economics*, *Industrial and Labor Relations Review*, the *Journal of Clinical Oncology*, and *The American Journal of Managed Care*. Dr. Cremieux's research has been cited in leading media outlets including *The Wall Street Journal* and *Forbes*.

Dr. Cremieux has frequently presented at leading legal, health care, and economics seminars on topics such as antitrust, class certification, health economics, and statistics, in both the United States and Canada. He has also been invited to teach courses on economics, statistics, health care, and antitrust at various schools including McGill University, Boston University, Harvard Medical School, and the Yale School of Management.

Prior to joining Analysis Group in 1997, Dr. Cremieux spent five years as a professor at the University du Québec à Montréal, and served as an adjunct professor from 1997 to 2018.

**EDUCATION**

- Ph.D.           University of California, Berkeley, CA  
*Areas of Specialization: Industrial Organization and Labor Economics*
- M.A.           Economics, University of California, Berkeley, CA
- B.A.           Economics, University of Maryland, College Park, MD

## PROFESSIONAL EXPERIENCE

August 1997–Present	Analysis Group, Boston, MA
August 1997–2018	University du Québec à Montréal, Canada <i>Adjunct Professor, Department of Economics</i>
June 1992–August 2000	University du Québec à Montréal, Canada <i>Assistant and Associate Professor, Department of Economics</i>
September 1987–June 1992	University of California, Berkeley, CA <i>Research and Teaching Assistant, Department of Economics</i>
September 1989–June 1990	San Francisco State University, CA <i>Lecturer, Department of Economics</i>

## SELECTED CASEWORK

- ***Pharmacyclics, et al. v. Fresenius Kabi USA, LLC, et al.***  
***Pharmacyclics, et al. v. Alvogen Pine Brook LLC, et al.***  
*United States District Court for the District of Delaware*  
Filed expert reports and provided testimony at deposition and trial on commercial success and the nexus between the economic success of a drug and the inventions disclosed and claimed in asserted patents.  
  
Drug: Imbruvica
- ***Radio Music License Committee, Inc. v. BMI***  
*United States District Court for the Southern District of New York*  
Filed expert reports and provided deposition testimony on the issue of appropriate licensing fees for performing rights.
- ***In re: Niaspan Antitrust Litigation***  
*United States District Court for the Eastern District of Pennsylvania*  
Filed an expert report and provided deposition testimony on the relevant antitrust market definition and the competitive effects of an alleged reverse-payment settlement.  
  
Drug: Niaspan
- ***In re: Loestrin 24 FE Antitrust Litigation***  
*United States District Court for the District of Rhode Island*  
Filed expert reports and provided deposition testimony on class certification and damages issues related to alleged reverse-payment settlements and an alleged anticompetitive product switching strategy involving oral contraceptives. Also provided testimony at class certification hearing.  
  
Drug: Loestrin 24/Minastrin 24

- ***The Hospital Authority of Metropolitan Government of Nashville and Davidson County, Tennessee, d/b/a Nashville General Hospital and American Federation of State, County, and Municipal Employees District Council 37 Health & Security Plan v. Momenta Pharmaceuticals, Inc. and Sandoz Inc.***

*United States District Court for the Middle District of Tennessee, Nashville Division*

Filed an expert report and provided deposition testimony on class certification issues related to delayed generic entry. Also provided testimony at class certification hearing.

Drug: Enoxaparin

- ***Danielle Seaman v. Duke University, et al.***

*United States District Court for the Middle District of North Carolina, Durham Division*

Filed expert reports and provided deposition testimony on class certification and damages issues related to an alleged no-poach agreement.

- ***In re: Merck Mumps Vaccine Antitrust Litigation;***

***United States of America ex rel, Stephen A. Krahling and Joan Wlochowski v. Merck & Co., Inc.***

*United States District Court for the Eastern District of Pennsylvania*

Filed an expert report and provided expert testimony on issues associated with class certification and damages related to alleged falsification of product label data with the intent to maintain a monopoly for mumps vaccine products.

Drug: Mumps vaccine products

- ***United States of America v. Teva Pharmaceuticals***

*United States District Court for the Southern District of New York*

Filed an expert report and provided expert testimony on issues associated with a drug sale in the context of an anti-kickback statute.

Drugs: Copaxone and Azilect

- ***Federal Trade Commission v. AbbVie, Inc., et al.***

*United States District Court for the Eastern District of Pennsylvania*

Filed an expert report and provided deposition testimony on market definition and damages issues related to an alleged sham patent litigation for a topical testosterone replacement therapy.

Drug: AndroGel

- ***In re: Namenda Direct Purchaser Antitrust Litigation***

*United States District Court for the Southern District of New York*

Filed an expert report and provided deposition testimony on class certification related to alleged “reverse-payment” settlements and an alleged anticompetitive product switching strategy involving Alzheimer’s disease therapies.

Drug: Namenda/Namenda XR

- ***Adel Tawfilis, DDS d/b/a Carmel Valley Center for Oral and Maxillofacial Surgery and Hamid A. Towhidian, M.D., individually and on behalf of all others similarly situated, v. Allergan, Inc.***

*United States District Court for the Central District of California Southern Division*

Filed an expert report and provided deposition testimony on class certification, market definition, and alleged antitrust issues related to an alleged anticompetitive licensing agreement.

Drug: Botox Cosmetic

- ***In re: Solodyn Antitrust Litigation***  
*United States District Court for the District of Massachusetts*  
Filed an expert report and provided deposition testimony on class certification related to alleged “reverse-payment” settlements.  
  
Drug: Solodyn
- ***In re: Disposable Contact Lens Antitrust Litigation***  
*United States District Court for the Middle District of Florida, Jacksonville Division*  
Filed expert reports, provided deposition testimony on class certification and alleged antitrust issues, and provided testimony at class certification hearing.
- ***In re: AndroGel Antitrust Litigation (II)***  
*United States District Court for the Northern District of Georgia, Atlanta Division*  
Filed an expert report and provided deposition testimony on market definition and economic issues related to alleged reverse-payment settlements made for a topical testosterone replacement therapy.  
  
Drug: AndroGel
- ***Apotex, Inc. and Apotex Corp. v. Kyorin Pharmaceutical Co., LTD. and Allergan, Inc.***  
*United States District Court for the District of Delaware*  
Filed an expert report and provided deposition testimony on market definition, liability, and damages issues related to an alleged anticompetitive product switching strategy involving ophthalmic antibiotic products.  
  
Drug: Zymar/Zymaxid
- ***Trana Discovery Inc. v. Southern Research Institute***  
*United States District Court for the District of Maryland*  
Filed an expert report and provided deposition testimony on damages issues related to alleged testing errors made in the drug discovery process.  
  
Drug: HIV compound
- ***Fidia Farmaceutici v. Sanofi-Aventis***  
*Before the Swiss Chambers’ Arbitration Institution*  
Filed expert reports and provided testimony at arbitration on a contract dispute involving issues related to marketing and distribution effort on sales of a viscosupplement for treating pain caused by osteoarthritis.  
  
Drug: Hyalgan
- ***Ischemia Research and Education Foundation, et al. v. Pfizer Inc.***  
*Superior Court of the State of California, County of Santa Clara*  
Filed an expert report and provided trial testimony on observational data.
- ***United States of America v. Pfizer***  
*United States District Court for the District of Massachusetts*  
Filed an expert report and provided deposition testimony addressing the alleged off-label promotion of a second-generation antipsychotic for use in pediatric patients.  
  
Drug: Geodon

- ***Abbvie v. Biogen Inc.***  
*American Arbitration Association*  
Filed an expert report and provided testimony in arbitration on an alleged breach of contract.  
Drug: Zinbryta
- ***United States of America v. Organon USA, Inc.***  
*United States District Court for the District of Massachusetts*  
Filed an expert report and provided expert testimony on issues associated with drug sales in the context of an anti-kickback statute.  
Drug: Remeron
- ***In re: Wellbutrin XL Antitrust Litigation***  
*United States District Court for the Eastern District of Pennsylvania*  
Filed expert reports and provided deposition testimony on damages issues.  
Drug: Wellbutrin
- ***Takeda Pharmaceuticals U.S.A., Inc. v. Amneal Pharmaceuticals, LLC, Par Pharmaceuticals, Inc., Watson Laboratories, Inc.***  
*United States District Court for the District of Delaware*  
Filed an expert report and provided expert testimony to assess the competitive dynamics and market factors that affect whether a prescription would be filled with the brand or generic versions of a drug.  
Drug: Colcrys
- ***BMI v. Pandora***  
*United States District Court for the District of New York, Second Circuit*  
Filed an expert report and provided expert testimony regarding the issue of appropriate licensing fees for performing rights.
- ***Umpqua Bank, et al. v. Target Corporation***  
*United States District Court for the District of Minnesota*  
Filed an expert report regarding the analysis of class certification issues related to the alleged economic harm to financial institutions associated with a data breach of a major retailer.
- ***Inter City Tire and Auto Center, Inc., et al. v. Michelin North America, Inc.***  
*United States District Court for the District of New Jersey*  
Filed an expert report and provided deposition testimony on issues related to damages.
- ***Warner Chilcott Company, LLC and Warner Chilcott (US), LLC v. Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd.***  
*United States District Court for the District of New Jersey and United States Court of Appeals for the Federal Circuit*  
Filed a declaration on issues related to a proposed preliminary injunction.  
Drug: Atelvia

- **Commercial Radio Tariffs – SOCAN (2011–2013); Re: Sound (2012–2014); CSI (2012–2013); ArtistI (2012–2014); AVLA/SOPROQ (2012–2017)**  
*Copyright Board of Canada*  
Provided expert testimony on the appropriate valuation and allocation of royalty rates in the presence of copyrighted exceptions.
- ***In re: Prograf Antitrust Litigation***  
*United States District Court for the District of Massachusetts*  
Filed an expert report and provided expert testimony on class certification issues.  
  
Drug: Prograf
- ***Mylan Pharmaceuticals Inc., et al. v. Warner Chilcott Public Limited Company, et al.***  
*United States District Court for the Eastern District of Pennsylvania*  
Filed an expert report and provided expert testimony on class certification issues.  
  
Drug: Doryx
- ***Janssen Pharmaceutical Inc. v. The Minister of Health and Apotex Inc.***  
*Federal Court of Canada*  
Filed an expert report involving statistical analyses relating to a patent infringement dispute.  
  
Drug: Ortho Try-Cyclen Lo
- ***Janssen Pharmaceutical Inc. v. Lupin Pharmaceuticals Inc.***  
*United States District Court for the District of New Jersey*  
Provided expert testimony in a dispute associated with the generic entry of oral contraceptives.  
  
Drug: Ortho Try-Cyclen Lo
- ***SODRAC v. CBC***  
*Copyright Board of Canada*  
Filed four expert reports and provided expert testimony on how to account for balance, technological neutrality, and the relative value of the different types of copies in valuation of reproduction copyright.
- ***In re: TFT-LCD (Flat Panel) Antitrust Litigation***  
*United States District Court for the Northern District of California, San Francisco Division*  
Provided expert testimony on liability- and damages-related issues associated with price-fixing allegations.
- ***In re: TFT-LCD (Flat Panel) Antitrust Litigation***  
*United States District Court for the Northern District of California, San Francisco Division*  
Supported expert analysis of class certification issues and damages related to price-fixing allegations.
- ***In re: Modafinil Antitrust Litigation***  
*United States District Court for the Eastern District of Pennsylvania*  
Supported an expert in the analysis of liability issues.  
  
Drug: Modafinil
- ***WPIX Inc., et al. v. Broadcast Music Inc.***  
*United States District Court for the Southern District of New York*  
Provided expert testimony on reasonable music license rates for local broadcast television.

- ***In re: Metoprolol Succinate End-Payor Antitrust Litigation***  
*United States District Court for the District of Delaware*  
Provided expert testimony on class certification issues.  
  
Drug: Metoprolol Succinate
- ***Bone Care International LLC and Genzyme Corporation v. Sandoz Inc. and Eagle Pharmaceuticals Inc.***  
*United States District Court for the District of Delaware*  
Filed an expert report and provided expert testimony on statistical issues related to a patent infringement dispute.  
  
Drug: Hectorol
- ***Apotex Inc. v. H. Lundbeck A/S***  
*Federal Court of Canada*  
Filed an expert report and provided expert testimony on the calculation of damages from patent infringement.  
  
Drug: Cipralelex (Escitalopram)
- ***Schering Corporation and MSP Singapore Company LLC v. Mylan Pharmaceuticals Inc. and Mylan Inc.***  
*United States District Court for the District of New Jersey*  
Filed an expert report on antitrust liability and damages.  
  
Drug: Vytorin and Zetia
- ***Genpharm ULC, Apotex Inc., and Cobalt Pharmaceuticals Inc. v. Lundbeck Canada Inc.***  
*Canadian Federal Court of Appeal*  
Filed an expert report and provided expert testimony on the impact of generic entry prior to scheduled patent expiry.  
  
Drug: Cipralelex (Escitalopram)
- ***Flonase Antitrust Litigation (All Actions) and Roxane Laboratories Inc. v. SmithKline Beecham Corp. d/b/a GlaxoSmithKline***  
*United States District Court for the Eastern District of Pennsylvania*  
Provided expert testimony on liability and damages issues associated with allegations relating to delayed generic entry.  
  
Drug: Flonase
- ***In re: Nexium Antitrust Litigation***  
*United States District Court for the District of Massachusetts*  
Supported an expert in the analysis of indirect purchaser class certification issues and damages.  
  
Drug: Nexium
- ***Ortho-Clinical Diagnostics Inc. v. Abbott Japan Co. Ltd.***  
*Japan Intellectual Property High Court, 4th Department*  
Filed an expert report on the statistical analysis of experimental results about antigen antibody binding in a patent invalidation dispute.

- ***Ortho-McNeil Pharmaceutical Inc. v. Watson Laboratories, Sandoz Inc., Lupin Pharmaceuticals Inc., and Lupin Ltd.***  
*United States District Court for the District of New Jersey*  
Filed an expert report and provided expert testimony in a dispute associated with the generic entry of oral contraceptives.  
Drug: Ortho Try-Cyclen Lo
- ***Hawaii Structural Ironworkers Pension Trust Fund v. Calpine Corporation***  
*Superior Court of the State of California, County of Santa Clara*  
Filed an expert report in the analysis of class certification issues in a Section 11 securities fraud litigation.
- ***Advanced Micro Devices Inc. and AMD International Sales and Service LTD. v. Intel Corporation and Intel Kabushiki Kaisha***  
*United States District Court for the District of Delaware*  
Supported multiple experts in the analysis of claims of anticompetitive behavior, including exclusionary conduct and monopolization.
- ***Pat Cason-Merenda and Jeffrey, et al. v. Detroit Medical Center, et al.***  
*United States District Court for the Eastern District of Michigan, Southern Division*  
Supported an expert in the analysis of class certification issues related to allegations of monopsony power.
- ***Discover Financial Services, DFS Services, and Discover Bank v. Visa U.S.A. Inc., et al. and American Express Travel Related Services Company Inc. v. Visa U.S.A. Inc., et al.***  
*United States District Court for the Southern District of New York*  
Supported multiple experts on liability, damages, and industry issues associated with an allegation of anticompetitive behavior.
- ***Louisiana Wholesale Drug Co. Inc. v. Sanofi-Aventis, Sanofi-Aventis U.S. LLC, and Aventis Pharmaceuticals Inc.***  
*United States District Court for the Southern District of New York*  
Provided expert testimony on liability and damages issues associated with allegations relating to delayed generic entry.  
Drug: Arava (Leflunomide)
- ***In re: Katrina Canal Breaches Consolidated Litigation***  
*United States District Court for the Western District of Texas*  
Supported an expert in the analysis of class certification issues related to alleged breach of duty with respect to damages from Hurricane Katrina.
- ***In re: Vioxx Third Party Payor Litigation***  
*Supreme Court for the State of New Jersey*  
Supported an expert in the analysis of class certification issues related to alleged adverse side effects of an overpayment for the drug.  
Drug: Vioxx



- ***Class Action v. Audit Bureau of Circulation***  
*Ontario Superior Court of Justice*  
Provided expert testimony in the analysis of class certification related to alleged fraud.
- ***In re: Bextra and Celebrex Marketing Sales Practices and Product Liability Litigation***  
*United States District Court for the Northern District of California, San Francisco Division*  
Supported an expert in conducting meta-analyses of clinical trials data to assess the cardiovascular safety profile of Celebrex.  
  
Drug: Bextra and Celebrex
- ***In re: NUI Securities, et al.***  
*United States District Court for the District of New Jersey*  
Provided damages analysis in a Rule 10b-5 securities fraud litigation.
- ***James Rizzi v. John Szoke Graphics Inc.***  
*Arbitration*  
Filed an expert report on alleged breach of contract.
- ***Axiom Plastics Inc. v. E.I. DuPont Canada Company***  
*Ontario Superior Court of Justice*  
Supported an expert in the analysis of class certification issues related to alleged price-fixing.
- ***In re: Royal Ahold Class Action***  
*United States District Court for the District of Maryland*  
Supported an expert and provided assistance in the settlement discussions in a class action stemming from the grocery conglomerate's accounting restatement.
- ***Conroy v. 3M Company***  
*United States District Court for Northern District of California*  
Supported an expert in the analysis of indirect purchaser class certification issues related to branded and private label adhesive products.
- ***Bluegreen Corporation v. David A. Siegel and David A. Siegel v. Bluegreen Corporation***  
*United States District Court for the Southern District of Florida*  
Supported an expert in the analysis of the economic, financial, and corporate governance implications of the adoption, by the Board of Directors of Bluegreen Corporation, of a shareholder rights plan.
- ***Bracco Diagnostics Inc. v. Amersham Health Inc., Amersham Health AS, and Amersham plc.***  
*United States District Court for the District of New Jersey*  
Supported an expert in the analysis of clinical trials examining the relative efficacy of two agents.  
  
Drugs: Iodixanol and Iohexol
- ***Heidi Turner Namiot v. Swiss Re Financial Product Corp***  
*United States District Court for the Southern District of New York*  
Filed expert report on issues related to termination.
- ***Ortho Biotech Products LP v. Amgen Inc. and Amgen USA Inc.***  
*United States District Court for the District of New Jersey*  
Provided expert testimony on the relative cost and efficacy of two leading erythropoietic agents in an antitrust case.  
  
Drug: Erythropoietin

- ***In re: Insurance Brokerage Antitrust Litigation***  
*United States District Court for the District of New Jersey*  
Supported an expert in the analysis of class certification issues related to alleged anticompetitive acts in the commercial insurance industry.
- **California State Auditor's Office**  
Drafted a report to the California State Auditor on the "cost-effectiveness and quality of health care in California State Prisons."
- ***Farmers Cooperative Elevator Co., et al. v. Akzo Nobel Inc., et al.***  
*Iowa District Court for Carroll County*  
Supported an expert in the analysis of indirect purchaser class certification issues related to alleged price-fixing of vitamin products.
- ***In re: NBR Antitrust Litigation***  
*United States District Court for the Western District of Pennsylvania*  
Supported an expert in the analysis of class certification issues related to alleged price-fixing and market allocation of acrylonitrile butadiene rubber.
- ***Paymaster Technologies v. United States of America***  
*United States Court of Federal Claims*  
Provided expert testimony in an intellectual property dispute.
- ***Ortho-McNeil Pharmaceutical Inc. v. Barr Laboratories Inc.***  
*United States District Court for the District of New Jersey*  
Provided expert testimony in a dispute associated with the generic entry of oral contraceptives.  
  
Drug: Ortho Try-Cyclen Lo
- ***In re: Microsoft I-V Cases***  
*Superior Court of the State of California for the City and County of San Francisco* Supported several experts in an analysis of potential damages resulting from alleged anticompetitive acts.
- ***Kellogg Company v. BASF AG, et al.***  
*United States District Court for the District of Columbia*  
Supported an expert in an analysis of potential damages resulting from alleged anticompetitive acts.
- ***United States of America v. Hoyts Cinemas Corporation and National Amusements Inc.***  
*United States District Court for the District of Massachusetts*  
Provided expert testimony on an alleged violation of the Americans with Disabilities Act.
- ***Susan Douglass v. Ernst & Young LLP***  
*United States District Court for the District of Massachusetts*  
Provided expert testimony on damages associated with allegations of illegal termination.
- ***Dr. Ben S. Branch, Trustee of Bank of New England Corporation v. Federal Deposit Insurance Corporation as Receiver of New Bank of New England, N.A., et al.***  
*United States District Court for the District of Massachusetts*  
Provided financial and economic analysis of the probability of bank failure using econometric and statistical analysis.

- ***In re: Brand Name Prescription Drugs Antitrust Litigation***  
*United States District Court for the Northern District of Illinois*  
Supported an expert in the analysis of potential damages associated with allegations of anticompetitive acts.
- ***Iain Fraser, et al. v. Major League Soccer LLC, et al.***  
*United States District Court for the District of Massachusetts*  
Supported an expert in the analysis of the potential impact of anticompetitive acts.
- ***Fitzpatrick v. Medical Resources Inc.***  
*Massachusetts Commission Against Discrimination*  
Provided statistical and econometric analysis of earnings levels and employment probability.
- ***Mr. Guecia v. Roman Catholic Archbishop of Boston, A Corporation Sole***  
*United States Superior Court of the State of Massachusetts for the County of Suffolk*  
Provided expert testimony on damages resulting from allegations of abuse (Pro bono).
- ***In re: Food and Drug Administration***  
Testified before the FDA as part of a labeling change.
- ***In re: Québec Assemblée Nationale***  
Testified before a House Committee on pharmaceutical pricing.
- ***In re: Food and Drug Administration***  
Testified before the FDA as part of a labeling request.
- ***In re: Québec Assemblée Nationale***  
Testified before a House committee on tobacco legislation.
- ***In re: Canadian House of Commons***  
Testified before a House committee on unemployment insurance.
- ***In re: Health Care Financing Administration***  
Testified before the HCFA as part of a cost-benefit analysis.

## ARTICLES & PUBLICATIONS

### Antitrust and Class Certification

“A Commissioners’ History of Cartel Enforcement in Europe: Multidimensional Comparison of Administrations,” Antoine Chapsal, Pierre Y. Cremieux, Jon Freimark, and Emmanuel Frot, *Journal of European Competition Law & Practice*; 11 (5–6): 302–308 (May–June 2020)

“Brief of Antitrust Law and Business School Professors, and Economists as Amici Curiae before the Supreme Court of the United States, National Football League, et al. v. Ninth Inning, Inc., et al.,” Signatory; No. 19-1098 (April 8, 2020)

“Brief of Antitrust Economists as Amici Curiae before the United States Court of Appeals for the 5<sup>th</sup> Circuit, Impax Laboratories, Inc. v. Federal Trade Commission,” Signatory; No. 19-60394 (October 10, 2019)

“Fiscal state aid: are US companies being unfairly targeted?” Pierre-Yves Cremieux, Marc Van Audenrode, and Dave Mishol, *Global Competition Review* (January 5, 2018)

“Calculating damages in price-fixing cases in the United States, Canada, and the European Union,” Pierre-Yves Cremieux, Marissa Ginn, and Marc Van Audenrode, *American Bar Association, Section of Litigation, Class Actions and Derivative Suits Litigation Committee* (May 1, 2017)

“A Comparison of Damage Theories in Price-Fixing Cases in the United States, Canada, and the European Union,” Pierre-Yves Cremieux, Marissa Ginn, and Marc Van Audenrode, *American Bar Association, Section of Litigation, Class Actions and Derivative Suits Litigation Committee* (January 31, 2017)

“Enforcement of Anti-collusion Laws Against Domestic and Foreign Firms,” Pierre-Yves Cremieux and Edward A. Snyder, *Journal of Law and Economics*; 59 (4): 775–803 (November 2016)

“Reverse Payments & Stock Prices: Smoking Gun or Damp Squib?” Pierre-Yves Cremieux, Ted Davis, Mark J. Lewis, and Paul E. Greenberg, *Law360* (August 24, 2016)

“Stock Prices Aren’t Enough for ‘Rule of Reason’ Analysis,” Pierre-Yves Cremieux, Ted Davis, Mark J. Lewis, and Paul E. Greenberg, *Law360*, (July 16, 2016)

“Use and Abuse: The Myth of Divided Antitrust Economics,” Pierre-Yves Cremieux and Aaron Yeater, *Global Antitrust Economics, Current Issues in Antitrust and Law & Economics*; D. Ginsburg, J. Wright: New York; Quality Books, Inc.; 15–21 (2016)

“Brief of Antitrust Economists as Amici Curiae before the United States Court of Appeals for the 1<sup>st</sup> Circuit, In re: Loestrin 24 Fe Antitrust Litigation,” Signatory; No. 14-2071, 15-1250; MDL No. 13-2474-S-PAS (D.R.I. Sept. 4, 2014) (August 27, 2015)

“Average Overcharge Models and Determining Individual Harm in Collective Actions,” Pierre-Yves Cremieux, Mark Lewis, and Dov Rothman, *Concurrences*; No. 2 (2015)

“Brief of Antitrust Economists as Amici Curiae before the United States Court of Appeals for the 3<sup>rd</sup> Circuit, King Drug Company of Florence, Inc., et al. v. SmithKline Beecham Corporation, et al.,” Signatory; No. 14–1243 (June 3, 2014)

“Applying Econometric Methods to Address Class Certification,” Pierre-Yves Cremieux, Adam Decter, Henry McFarland, Philip Nelson, Dov Rothman, and David Smith, in *Econometrics: Legal, Practical and Technical Issues (Second Edition)*, American Bar Association Antitrust Law Section, (March 2014)

“Brief of Antitrust Economists as Amici Curiae before the Supreme Court of the United States, Federal Trade Commission v. Actavis Inc. et al.,” Signatory; No. 12–416 (February 28, 2013)

“The Role of Experts in Antitrust Class Certification,” Pierre-Yves Cremieux, George Kosicki, and Tammy Sisitsky, *Antitrust Class Actions Handbook* (2010)

“A New Approach to Antitrust Class Certification,” Pierre-Yves Cremieux, Ian Simmons, and Edward A. Snyder, *Law 360* (June 14, 2010)

“Proof of Common Impact in Antitrust Litigation: The Value of Regression Analysis,” Pierre-Yves Cremieux, Ian Simmons, and Edward A. Snyder, *George Mason Law Review*; 17 (2010)

“Assessing Conflict, Impact, and Common Methods of Proof in Intermediate Indirect-Purchaser Class Action Litigation,” Pierre-Yves Cremieux, Adam Decter, Steven Herscovici, and Robert Mascola, *American Bar Association Economics Committee Newsletter*; 6 (1): 4–10 (2006)

## Health

“Improved Outcomes with High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment in Haiti,” Kathleen F. Walsh, Stalz Charles Vilbrun, Ariadne Souroutzidis, Sobieskye Delva, Guy Joissaint, Laurent Mathurin, Oksana Ocheretina, Pierre-Yves Cremieux, Jean William Pape, Serena P. Koenig, *Clinical Infectious Diseases*; 69 (4): 717–19 (2019)

“Characteristics and Psychological Consequences of Sexual Assault in Haiti,” with Marie M. Deschamps, Harry Theodore, Marie Irdnie Christophe, Ariadne Souroutzidis, Mark Meiselbach, Tatiana Bell, Christian Perodin, Stravinsky Anglade, Jessy Devieux, Pierre-Yves Cremieux, and Jean W. Pape, *Violence and Gender*; 6 (2): 124–130 (2019)

“Diagnostic Yield of Active Case Finding for Tuberculosis and HIV at the Household Level in Slums in Haiti,” Vanessa R. Rivera, Marc Antoine Jean Juste, Samantha Gluck, Harrison Reeder, Jeanwilkins Sainristil, Pierrot Julma, Mireille Peck, Patrice Joseph, Oksana Ocheretina, Christian Perodin, Rode Secours, Maria Duran-Mendicuti, Lauren Hashiguchi, Pierre-Yves Cremieux, Serena P. Koenig, and Jean W. Pape, *The International Journal of Tuberculosis and Lung Disease*; 21 (11): 1140–1146 (2017)

“Retention in Care Among Patients With Early HIV Disease in Haiti,” Kelly A. Hennessey, Taina Dadaille Leger, Vanessa R. Rivera, Adias Marcelin, Margaret L. McNairy, Colette Guiteau, Jessy G. Devieux, Yvel Marcelin, Benedict Charles, Pierre-Yves Cremieux, Serena P. Koenig, and Jean W. Pape, *Journal of the International Association of Providers of AIDS Care*; 16 (6): 523–526 (2017)

“Health Services Utilization Among Fee for Service Medicare and Medicaid Patients Under Age 65 with Behavioral Health Illness at an Urban Safety Net Hospital,” Ramon S. Cancino, Brian W. Jack, John Jarvis, Alice Kate Cummings, Ellie Cooper, Pierre-Yves Cremieux, and James F. Burgess, Jr., *Journal of Managed Care & Specialty Pharmacy*; 23 (7): 781–788 (2017)

“Same-Day HIV Testing with Initiation of Antiretroviral Therapy versus Standard Care for Persons Living with HIV: a Randomized Unblinded Trial,” Serena P. Koenig, Nancy Dorvil, Jessy G. Dévieux, Bethany L. Hedt-Gauthier, Cynthia Riviere, Mikerlyne Faustin, Kerlyne Lavoile, Christian Perodin, Alexandra Apollon, Limathe Duverger, Margaret L. McNairy, Kelly A. Hennessey, Ariadne Souroutzidis, Pierre-Yves Cremieux, Patrice Severe, and Jean W. Pape, *PLOS Medicine*; 14 (7): e1002357 (2017)

“Learning From Social Media For Adverse Event Reporting,” Mei Sheng Duh, Brian Ellman, Marc Van Audenrode, Paul Greenberg, and Pierre-Yves Cremieux, *Law360* (May 23, 2017)

“Can Social Media Data Lead to Earlier Detection of Drug-Related Adverse Events?” Mei Sheng Duh, Pierre-Yves Cremieux, Marc Van Audenrode, Francis Vekeman, Paul Karner, Haimin Zhang, and Paul Greenberg, *Pharmacoepidemiology & Drug Safety*; 25 (12): 1425–1433 (2016)

“An Analysis of the Economic Impact of the Mirebalais National Teaching Hospital on the Haitian Economy: An Input-Output Approach,” Michel-Ange Pantal, Peterson Abnis I. Faure, Jean-Gregory Jerome, Jean-Claude Mugunga, Markus Von Wartburg, Matthew Peckarsky, Marc Van Audenrode, and Pierre-Yves Cremieux, *Journal of Eastern Caribbean Studies*; 40 (3): 234–250 (2015)

“A Second Look at the Association between Gender and Mortality on Antiretroviral Therapy,” Serena Koenig, Alexandra Bornstein, Karine Severe, Elizabeth Fox, Jessy Devieux, Patrice Severe, Patrice Joseph, Adias Marcelin, Dgndy Alexandre Bright, Ngoc Pham, Pierre-Yves Cremieux, and Jean William Pape, *PLOS One*; 10 (11): e0142101 (2015)

“Policy Makers’ Views of Obesity-Related Challenges Around the World,” Pierre-Yves Cremieux, *PharmacoEconomics*; 33 (7): 619–628 (July 2015)

“For a Step Change to Curb the Obesity Epidemic,” Christian Frois and Pierre-Yves Cremieux, *PharmacoEconomics*; 33 (7): 613–617 (July 2015)

“Gap Between Evidence and Patient Access: Policy Implications for Bariatric and Metabolic Surgery in the Treatment of Obesity and its Complications,” Amarpreet Chawla, Chia-Wen Hsiao, Martha Romney, Ricardo Cohen, Francesco Rubino, Philip Schauer, and Pierre-Yves Cremieux, *PharmacoEconomics*; 33 (7): 629–641 (July 2015)

“Superior Outcomes and Lower Outpatient Costs with Scale-up of Antiretroviral Therapy at the GHESKIO Clinic in Port-au-Prince, Haiti,” Cynthia Riviere, Elizabeth Faust, Thane Miller, Eduard J Beck, Elaine Baruwa, Patrice Severe, Karine Severe, Claudia Thomas Riché, Rachelle Cassagnol, Sidney Atwood, Morgan Esperance, Lauren Webster, Pierre-Yves Cremieux, Jean William Pape, and Serena P Koenig, *Journal of Acquired Immune Deficiency Syndromes*; 66 (4): e:72–9 (2014)

“Weighing the Economic Impact and Clinical Benefits of Bariatric Surgery in Morbidly Obese Patients with Diabetes: A Review,” Pierre-Yves Cremieux, Sara Eapen, Stephen Trask, and Arindam Ghosh, *Canadian Journal of Diabetes* (2011)

“Weighing the Benefits: The Economics of Obesity Surgery,” John Dawson, Pierre-Yves Cremieux, and Arindam Ghosh, *Contingencies* (2010)

“Economic Impact of the Clinical Benefits of Bariatric Surgery in Diabetes Patients With BMI  $\geq 35\text{kg/m}^2$ ,” Samuel Klein, Arindam Ghosh, Pierre Y. Cremieux, Sara Eapen, and Tamara J. McGavock, *Obesity* (2010)

“Methodological Issues in a Meta-Analysis,” Letter to the Editor, *Hepatology*; 52 (1): 395–397 (2010)

“The impact of bariatric surgery on comorbidities and medication use among obese patients,” Pierre-Yves Cremieux, Severine Ledoux, Christine Clerici, Francois Cremieux, and Marris Buessing, *Obesity Surgery*; 20 (7): 861–870 (2010)

“Assessing The Relationship Between Compliance With Antidepressant Therapy And Employer Costs Among Employees In The United States,” Howard Birnbaum, Rym Ben-Hamadi, David Kelley, Matthew Hsieh, Brian Seal, Evan Kantor, Pierre Y. Cremieux, and Paul E. Greenberg, *Journal of Occupational and Environmental Medicine*; 52 (2): 115–124 (2010)

“Exact and efficient inference procedure for meta-analysis and its application to the analysis of 2x2 tables with all available data but with artificial continuity correction,” Lu Tian, Tianxi Cai, Marc A. Pfeffer, Nikita Piankov, Pierre-Yves Cremieux, and L. J. Wei, *Biostatistics*; 10: 275–281 (2009)

“Hospital Performance in a Non-Competitive Environment,” Daniel Bilodeau, Pierre-Yves Cremieux, and Pierre Ouellette, *Applied Economics*; 41 (2-6): 459–468 (2009)

“Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs,” Howard G. Birnbaum, Jasmina I. Ivanova, Seth Samuels, Matthew Davis, Pierre Y. Cremieux, Amy L. Phillips, and Dennis Meletiche, *Current Medical Research and Opinion*; 25 (4): 869–877 (2009)

“A Study on the Economic Impact of Bariatric Surgery,” Pierre-Yves Cremieux, Henry Buchwald, Scott Shikora, Arindam Ghosh, Elaine Yang, and Marris Buessing, *American Journal of Managed Care*; 14 (9): 589–597 (2008)

“The Economic Consequences of Generic Substitution for Antiepileptic Drugs in a Public Payer Setting: The Case of Lamotrigine,” Mei Sheng Duh, Frederick Andermann, Pierre Emmanuel Paradis, Jennifer Weiner, Ranjani Manjunath, and Pierre-Yves Cremieux, *Disease Management*; 10 (4): 216–25 (2007)

“The Economic Impact of a Partnership Measurement Model of Disease Management: Improving Cardiovascular Outcomes in Nova Scotia,” Pierre-Yves Cremieux, Pierre Fortin, Marie-Claude Meilleur, Terrence Montague, and Jimmy Royer, *Healthcare Quarterly*; 10 (2): 36–44 (2007)

“Do Drugs Reduce Utilization of Other Health Care Resources?” Pierre-Yves Cremieux, Pierre Ouellette, and Patrick Petit, *Pharmacoeconomics*; 25 (3): 209–21 (2007)

“The Value of Antihypertensive Drugs: A Perspective on Medical Innovation,” David Cutler, Genia Long, Ernst Berndt, Jimmy Royer, Andrée-Anne Fournier, Alicia Sasser, and Pierre-Yves Cremieux, *Health Affairs*; 26 (1): 97–110 (2007)

“Pharmaceutical Spending and Health Outcomes,” Pierre-Yves Cremieux, Denise Jarvinen, Philip Merrigan, and Genia Long, *Pharmaceutical Innovation: Incentives, Competition and Cost-Benefit Analysis in International Perspective*; Frank A. Sloan and Chee-Ruey Hsieh (Ed.), Cambridge University Press, New York (2007)

“Relationship Between Hemoglobin Level and Quality of Life in Anemic Patients with Chronic Kidney Disease Receiving Epoetin Alfa,” Patrick Lefebvre, Francis Vekeman, Brenda Sarokhan, Christopher Enny, Robert Provenzano, and Pierre-Yves Cremieux, *Current Medical Research and Opinions*; 22: 1929–37 (2006)

“Les tendances dans la consommation de médicaments au Canada de 1994 à 2002 : Une analyse descriptive,” Pierre-Yves Cremieux, Dominique Latremouille-Viau, Philip Merrigan, and Pierre Ouellette, *Le Point en administration de la santé et des services sociaux* ; 2 (2): 24–29 (2006)

“The Relative Dosing of Epoetin Alfa and Darbepoetin Alfa in Chronic Kidney Disease,” Pierre-Yves Cremieux, Marc Van Audenrode, and Patrick Lefebvre, *Current Medical Research and Opinion*; 22 (12): 2329–36 (2006)

“Dose Conversion and Cost Effectiveness of Erythropoietic Therapies in Chemotherapy-related Anemia: A Canadian Application,” Pierre-Yves Cremieux, Francis Vekeman, and Patrick Lefebvre, *Journal of Oncology Pharmacy Practice*; 12: 1–14 (2006)

“L’impact des dépenses en médicaments sur les coûts de santé et l’état de santé des populations,” Pierre-Yves Cremieux, *Les Cahiers du Geirso*; 1 (4): 88–102 (2005)

“Dose Conversion and Cost-Effectiveness of Erythropoietic Therapies in Chemotherapy-related Anemia: A Meta-Analysis,” James Rosberg, Rym Ben-Hamadi, Pierre-Yves Cremieux, John Fastenau, and Catherine Piech, *Clinical Drug Investigation*; 25 (1): 33–48 (2005)

“Hospital Cost Flexibility in the Presence of Many Outputs: A Public-Private Comparison,” Pierre-Yves Cremieux, Pierre Ouellette, François Rimbaud, and Stéphane Vigeant, *Health Care Management Science*; 8: 111–22 (2005)

“Relationship Between Hemoglobin Levels and Quality of Life During Radiation Therapy Plus Concomitant or Sequential Chemotherapy in Patients with Cancer and Anemia Treated with Epoetin Alfa,” Daniel Shasha, Pierre-Yves Cremieux, and Louis Harrison, *Journal of the National Comprehensive Cancer Network*; 2 (5): 509–17 (2004)

“Cost-Minimization Analysis of Once-Weekly vs. Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia,” Pierre-Yves Cremieux, John Fastenau, George Kosicki, Catherine Piech, and A. Mark Fendrick, *Journal of Managed Care Pharmacy*; 531–37 (2004)

“Incidence and Costs of Accidents Among Attention-Deficit/Hyperactive Disorder Patients,” Andrine Swensen, Howard Birnbaum, Rym Ben-Hamadi, Paul Greenberg, Pierre-Yves Cremieux, and Kristina Secnik, *Journal of Adolescent Health*; 35 (4): 346–47 (2004)

“Public and Private Pharmaceutical Spending as Determinants of Health Outcomes in Canada,” Pierre-Yves Cremieux, Marie-Claude Meilleur, Pierre Ouellette, Patrick Petit, Martin Zelder, and Ken Potvin, *Health Economics*; 14: 107–16 (2004)

“Measuring Hospital Efficiency in the Presence of Quasi-Fixed Inputs: An Analysis of Quebec Hospitals,” Daniel Bilodeau, Pierre-Yves Cremieux, Brigitte Jaumard, Pierre Ouellette, and Tsévi Vovor, *Journal of Productivity Analysis*; 21 (2): 183–99 (2004)

“Cost Effectiveness of rHuEPO in Oncology,” Pierre-Yves Cremieux, Ellison Dial, Mark Gustafson, Brenda Sarokhan, and Mitchell Slavin, *Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology: Scientific and Clinical Aspects of Anemia in Cancer*, M.R. Nowrousian (Ed.), Springer Wien, New York (2002)

“Hospital Technology in a Non-Market Health Care System,” Daniel Bilodeau, Pierre-Yves Cremieux, and Pierre Ouellette, *Southern Economic Journal*; 68 (3): 511–29 (2002)

“Relationship Between Changes in Hemoglobin Level and Quality of Life During Chemotherapy in Anemic Cancer Patients Receiving Epoetin Alfa Therapy,” Jeffrey Crawford, David Cella, Charles Cleeland, Pierre-Yves Cremieux, George Demetri, Brenda Sarokhan, Mitchell Slavin, and John Glaspy, *Cancer*; 95 (4): 888–95 (2002)

“Statistical Explanations for a Community-Based Study of Once-Weekly Epoetin Alfa Therapy in Patients Receiving Chemotherapy,” Janice Gabilove, Brenda Sarokhan, and Pierre-Yves Cremieux, *Journal of Clinical Oncology*; 20 (11): 2757–58 (2002)

“The costs of cancer: cancer-related conditions can add dramatically to overall costs of care,” Pierre-Yves Cremieux, Mitchell Slavin, A. Mark Fendrick, Tom Hiriak, and George Kosicki, *Journal of Managed Care Medicine*; 5 (12): 8–12 (2001)

“Anemia-Related Costs for Cancer Patients,” Arnold Barnett, Pierre-Yves Cremieux, A. Mark Fendrick, Martine George, and Mitchell Slavin, *Journal of Managed Care Medicine*; 5 (12): 14–16 (2001)

“L’évolution du régime d’assurance-médicament,” Jean-Pierre Bluteau, Pierre-Yves Cremieux, and Pierre Ouellette, *Annuaire du Québec*; Éditions Fides (2001)

“Pharmaceutical Spending and Health Outcomes in the United States,” Pierre-Yves Cremieux, Pierre Ouellette, Marie-Claude Meilleur, Stephanie Leong, Paul Greenberg, and Howard Birnbaum, *Investing in Health: The Social and Economic Benefits of Health Care Innovation*, I. Farquar, K. Summers, and A. Sorkin, (Ed.), Elsevier Science, New York, NY (2001)

“L’évaluation de l’efficience budgétaire des CLSC au Québec à partir de la méthode DEA,” Pierre-Yves Cremieux, Denis Gadbois, Brigitte Jaumard, Pierre Ouellette, and Tsévi Vovor, *L’Actualité Économique*; 77 (3): 409–24 (2001)

“Omitted Variable Bias and Hospital Costs,” Pierre-Yves Cremieux and Pierre Ouellette, *Journal of Health Economics*; 20 (2): 271–83 (2001)



- “Actual and Perceived Impacts of Tobacco Regulation on Restaurants and Firms,” Pierre-Yves Cremieux and Pierre Ouellette, *Tobacco Control*; 10: 33–7 (2001)
- “Understanding the Pharmacoeconomic Profile of Cancer,” Howard Birnbaum, Pierre-Yves Cremieux, and Paul Greenberg, *ONE: Oncology Economics*; 1 (10): 36–9 (2000)
- “Dépenses de santé, indicateurs de santé et impact de nouvelles pharmacothérapies,” Pierre-Yves Cremieux, Jacques LeLorier, and Pierre Ouellette, report to the Commission of Social Affairs, Quebec National Assembly (February 15, 2000)
- “Diagnosing the Illness,” Pierre-Yves Cremieux and Pierre Ouellette *Policy Options*; 12 (4): 12–4 (2000)
- “Costs Associated with Anemia and Cancer,” Pierre-Yves Cremieux, Matthew Gubens, Michael Holland, and Mitchell Slavin, *ONE: Oncology Economics*; 1 (11): 1–7 (2000)
- “Management of Major Depression in the Workplace: Impact on Employee Work Loss,” Howard Birnbaum, Pierre-Yves Cremieux, Paul Greenberg, and Ronald Kessler, *Disease Management and Health Outcomes*; 7 (3): 163–71 (2000)
- “Cost of Outpatient Blood Transfusion in Cancer Patients,” Pierre-Yves Cremieux, Barbara Barrett, Kenneth Anderson, and Mitchell Slavin, *Journal of Clinical Oncology*; 18 (14): 2755–61 (2000)
- “The Costs of Cancer to a Major Employer in the United States: A Case-Control Analysis,” Arnold Barnett, Howard Birnbaum, Pierre-Yves Cremieux, A. Mark Fendrick, and Mitchell Slavin, *American Journal of Managed Care*; 6 (11): 1243–51 (2000)
- “Hospital Cost Function in a Non-Market Health Care System,” Daniel Bilodeau, Pierre-Yves Cremieux, and Pierre Ouellette, *The Review of Economics and Statistics*; 82 (3): 1–11 (2000)
- “Using Health Care Claims Data for Outcomes Research and Pharmacoeconomic Analyses,” Howard Birnbaum, Pierre-Yves Cremieux, Paul Greenberg, Jacques LeLorier, JoAnn Ostrander, and Laura Venditti, *Pharmacoeconomics*; 16 (1): 1–8 (1999)
- “Public and Private Health Care Spending as Determinants of Health Outcomes,” Pierre-Yves Cremieux, Pierre Ouellette, and Caroline Pilon, *Health Economics*; 8: 627–39 (1999)
- “Cost-Effectiveness, Quality-Adjusted Life Years, and Supportive Care: Recombinant Human Erythropoietin as Treatment of Cancer-Associated Anemia,” Pierre-Yves Cremieux, Stan Finkelstein, Ernst Berndt, Jeffrey Crawford, and Mitchell Slavin, *Pharmacoeconomics*; 16 (5): 459–72 (1999)
- “Tackling Costs One Disease at a Time,” Paul Greenberg, Mary Barton, Howard Birnbaum, Pierre-Yves Cremieux, Mitchell Slavin, Fabian D’Souza, and Becky Auerbach, *Business and Health*; 5: 31–7 (1999)
- “Pharmacoeconomics and Health Policy: Current Applications and Prospects for the Future,” Paul Greenberg, Almudena Arcelus, Howard Birnbaum, Pierre-Yves Cremieux, Jacques LeLorier, Pierre Ouellette, and Mitchell Slavin, *Pharmacoeconomics*; 16 (5): 1–8 (1999)
- “La performance des CLSC au Québec,” Pierre-Yves Cremieux, Pierre Ouellette, and Denis Gadbois, *l’Actualité Économique*; 74 (2): 157–81 (1998)
- “Étude d’impact du projet de loi sur le tabac,” (Impact Report on the Proposed Tobacco Law), Pierre-Yves Cremieux, Pierre Fortin, Frederic Lavoie, Pierre Ouellette, and Yvan St. Pierre, in *Ministry of Health and Social Services* (1997)

“Une analyse du contexte budgétaire de l’activité médicale au Québec,” Pierre-Yves Cremieux and Pierre Ouellette, *Le Médecin du Québec* (1997)

### **Labor**

“Review of the book ‘Monopsony in Law and Economics’ by Roger D. Blair and Jeffrey L. Harrison,” Pierre-Yves Cremieux, *Journal of Economic Literature*; 49 (4): 1289–91 (2011)

*Employment, Earnings Supplements, and Mental Health: A Controlled Experiment*, Pierre-Yves Cremieux, Paul Greenberg, Ronald Kessler, Philip Merrigan, and Marc Van Audenrode, Social Research and Demonstration Corporation Working Paper; 4 (1) (2004)

“Le marché du travail et l’évolution des salaires dans le transport aérien aux Etats-Unis: L’effet de la déréglementation de 1978,” Pierre-Yves Cremieux, *Economie et Prévision* (1998)

“Why Strike Insurance is Unilateral: Evidence from the Airline Industry’s Mutual Aid Pact,” Pierre-Yves Cremieux, *Journal of Labor Research*; 17 (2) (1996)

“The Effect of Deregulation on Employee Earnings: Pilots, Flight Attendants, and Mechanics: 1959–1992,” Pierre-Yves Cremieux, *Industrial and Labor Relations Review*; 49 (2): 223–42 (1996)

“Mergers and Bargaining in the U.S. Airline Industry,” Pierre-Yves Cremieux and Marc Van Audenrode, *Review of Labour Economics and Industrial Relations*; 10 (2) (1996)

“Is the U.S./Canada Unemployment Gap Truly Large? A Labor Flow Analysis,” Pierre-Yves Cremieux and Marc Van Audenrode, *The Flow Approach to Labor Market Analysis*, Ronald Schettkat (Ed.), Routledge, New York (1996)

“Unemployment Insurance and Job Search Productivity,” Pierre-Yves Cremieux, Pierre Fortin, Paul Storer, and Marc Van Audenrode, *Insurance Program Evaluation Report, Human Resources Development Canada* (1995)

“The Impact of Unemployment Insurance on Job-Search Productivity, the Reservation Wage, the Probability of Re-Employment, and the Post-Displacement Wage,” Pierre-Yves Cremieux, Pierre Fortin, Paul Storer and Marc Van Audenrode, *Insurance Program Evaluation Report, Human Resources Development Canada* (1995)

“L’évolution macroéconomique et la question budgétaire au Québec,” Pierre-Yves Cremieux, Pierre Fortin, and Marc Van Audenrode, *Health and Welfare Council* (1994)

### **Other**

“What Attorneys Should Know About FDA’s MedWatch Data,” Mei Duh, Pierre-Yves Cremieux, Paul Greenberg, and Brian Ellman, *Law360* (January 29, 2014)

“How to Use Clinical Trial Data in Court,” Pierre-Yves Cremieux, Arindam Ghosh, and Lisa Pinheiro, *Law360* (July 3, 2012)

“Getting the Most Out of Your Experts,” Pierre-Yves Cremieux, Elizabeth Eccher, and Steven Herscovici, *Expert Alert, American Bar Association Litigation Section* (2007)

“Product Liability in the Pharmaceutical Industry,” Pierre-Yves Cremieux and Paul Greenberg, *Update Magazine* (2004)

“The Cost-Effectiveness and Quality of Health Care in California’s State Prisons,” Coauthored report to the California State Auditor’s Office (January 2000)

“The Privatization Process of the Publicly Owned Companies in Haiti: Observations and Recommendations,” (in French with André Marcoux). Report of the observation mission of “Concertation Pour Haïti” on the privatization of publicly owned companies (November 1996)

“The Economic and Social Impact of the Community Service in Four Districts of the City of Montreal,” (joint work in French). Service aux collectivités de l’UQAM (October 1996)

“The Level of the Minimum Wage,” *Le Devoir* (in French, May 15, 1996)

“A Profile of the Work Force in the Rosemont Petite-Patrie District,” Report to the CDEC Rosemont Petite-Patrie within the framework of the ANGUS development project (in French, October 1995)

“Rise in the Minimum Wage: Little Risk for Employment and Competitiveness,” *La Presse* (in French, June 2, 1995)

“Une analyse quantitative de la position des Québécois face à l’aide sociale,” (A Quantitative Analysis of Quebecer’s Position Towards Welfare). Report to the Commission on Welfare Reform (January 1995)

“For a Contribution of the FTQ to the Development and Promotion of Tourism in Quebec,” Feasibility study (joint work in French) (December 1994)

“The Last Federal Budget and the Unemployed: Surprising and Disturbing Issues,” Pierre-Yves Cremieux, Pierre Fortin, and Marc Van Audenrode, *La Presse* (in French) and *Ottawa Citizen* (in English) (March 9, 1994)

“Question de niveau,” *La Presse* (December 10, 1993)

## **SELECTED PRESENTATIONS & SPEAKING ENGAGEMENTS**

“Economists Roundtable with the Competition Bureau,” roundtable presented at Canadian Bar Association (April 27, 2016)

“Where are we on Class Certification? Examples from Health Care and Pharmaceutical Cases,” webinar presented by the American Bar Association (ABA) Antitrust Law Section (March 15, 2016)

“Enforcement of Anti-Collusion Laws Against Domestic and Foreign Firms” seminar presented at Yale School of Management, *Problems With Global Antitrust Enforcement* Conference (February 19–20, 2016)

“Antitrust Challenges to Patent Settlements after *FTC v. Actavis*,” webinar presented by Ballard Spahr (June 25, 2013)

“Reverse Payment Patent Settlements: The Supreme Court Has Spoken,” teleconference presented by ABA Antitrust Law Section and WilmerHale (June 18, 2013)

“The Economics of Obesity,” presented at the Cleveland Clinic’s 7<sup>th</sup> Annual Obesity Summit: Science and Practice of Obesity Management (October 4–5, 2012)

“Proving Common Impact in Antitrust Class Certification,” seminar presented at The University of Chicago Gleacher Center (May 12, 2010)

“The Cost-Effectiveness of Surgery for Type 2 Diabetes Mellitus,” presented at the First Canadian Summit on Surgery for T2DM (May 2010)

“Global Antitrust Enforcement, an Empirical Assessment of Protectionism,” presented at the Boston Bar Association (March 2010)

“A Period of Increased Risk for Competition Policy,” presented at the Centro de Estudios Publicos, Santiago, Chile (September 2009)

“The Economic Impact of Bariatric Surgery, an ROI Analysis,” presented to the National Business Group on Health, Institute on the Costs and Health Effects of Obesity (February 2009)

“A Study on the Economic Impact of Bariatric Surgery,” presented at the 94th Annual Clinical Congress of the American College of Surgeons (October 2008)

“Economics and Cost-Effectiveness of Surgery for Diabetes,” presented at the 1st World Congress on Interventional Therapies for Type 2 Diabetes (September 2008)

“Developments in Class Certification in the U.S. and Abroad,” presented at an ABA Teleconference (June 2008)

“The Prevalence of Pediatric Mental Illness and Treatment in the United States,” presented at the 2nd International Conference on the Pharmaceutical Life Cycle (October 2007)

“Biostatistics and Pharmacoeconomics: Introduction to Statistical Methods and Applications to Medical Scientific Literature,” presented at various medical schools, universities, and hospitals (2006–2007)

“Can We Put a Price on the Value of Medicine?” presented at the Summit on the Value of Medicine (February 2007)

“Biostatistics and Pharmacoeconomics: Introduction to Statistical Methods in the Medical Literature,” presented at GEIRSO (October 2006)

“Evaluating the Cost-Benefit of Bariatric Surgery and Laparoscopic Band,” presented at the World Congress Conference on Implementation and Cost Benefit of Workplace Weight Management Strategies (June 2006)

“The Impact of Bariatric Surgery on Health Outcomes and Pharmacological Treatment Among Obese Patients in an Employed Population,” presented at the International Society for Pharmacoeconomics and Outcomes Research (May 2006)

“Using Economic Experts in the Battle for Predominance,” presented at Law Seminars International (February 2006)

“Litigating Mass Tort in Canada: The Nexus of Epidemiology, Economics, and Law,” presented at Insight Conference on Drug Safety (January 2006)

“L’utilisation d’approches épidémiologiques et statistiques pour la défense des recours collectifs concernant les produits défectueux,” presented at Conférence Insight sur le système de santé au Québec (January 2006)

“L’impact des dépenses en médicaments sur les coûts de santé et l’état de santé des populations,” presented at Institut Canadien de la retraite et des avantages sociaux (September 2004)

“L’impact des dépenses en soins de santé et médicaments sur la santé de la population : une analyse provinciale,” presented at Société canadienne de science économique (May 2004)

“Providing Economic Analysis in the Context of Antitrust Litigation,” presented at Brandeis University (October 2003)

- “A Health Economics Perspective on Quality-of-Life Versus Life-preserving Therapies,” presented at Business and Health Consensus Panel (June 2000)
- “Health Economics and Pharmacoeconomic Analysis,” presented at Harvard Medical School (February 2000)
- “Economic Trends in the Health Care System,” presented at Association Québécoise des Pharmaciens Propriétaires (December 1999)
- “A DEA Application to Hospital Performance Analysis in a Non-Competitive Environment,” presented at Canadian Economic Association (June 1999)
- “The Cost-Effectiveness of r-HuEPO in Cancer Patients with Chemotherapy-Related Anemia,” presented at Edmonton University Hospital (May 1999)
- “The Cost-Effectiveness of r-HuEPO in Cancer Patients with Chemotherapy-Related Anemia,” presented at Winnipeg University Hospital (May 1999)
- “Pharmacoeconomics and Cost-Effectiveness,” presented at Harvard Medical School (February 1998)
- “The Economics Most Worth Knowing,” lecture to the sales force of a major pharmaceutical company (January 1998)
- “Acute Care Hospitals in Quebec: A Performance Analysis Based on Panel Data,” 6<sup>ème</sup> journées d'étude des données de Panel (June 1996)
- “Is the US/Canada Unemployment Gap Truly Large? A Labor Flow Analysis,” presented at Canadian Economics Association (June 1995)
- “The Effect of Deregulation on Employee Earnings: Pilots, Flight Attendants, and Mechanics: 1959-1992,” 5<sup>ème</sup> journée d'étude des données de panel (June 1994)
- “L'Évolution macroéconomique et la question budgétaire au Québec,” presented at Health and Welfare Council (November 1994)
- “Is the U.S./Canada Unemployment Gap Truly Large? A Labor Flow Analysis,” presented at Conference on Labor Flows (December 1994)
- “Rent Sharing in the Airline Industry: Evidence from Mergers and Acquisitions,” presented at Société canadienne de science économique (May 1993)
- “Rent Sharing in the Airline Industry: Evidence from Mergers and Acquisitions,” presented at University of California, Berkeley (June 1993)
- “The Effect of Strike Insurance on Labor Earnings,” presented at Montreal University, UQAM, Laval University, (January 1992)

## **ACADEMIC RESEARCH GRANTS**

**Co-Principal Investigators:** Serena Koenig and Patrice Severe

**Other Investigators:** Pierre-Yves Cremieux, Paul Sax, Behtany Hedt, Rafael Campo, and Dennis Israelski

**Funding source:** Gilead Sciences Inc. (2019–2022)

**Title:** “A Randomized Non-Inferiority Trial to Compare the Efficacy of Switching from Protease-Inhibitor Based Second-Line Therapy to Bictegravir-Tenofovir Alafenamide-Emtricitabine in

Virologically Suppressed Adults in Haiti”

**Amount:** \$1,429,757

**Co-Principal Investigators:** Jean William Pape and Serena Koenig

**Other Investigators:** Colette Guiteau Moise, Pierre-Yves Cremieux, and Jessy G. Devieux

**Funding source:** Viiv Healthcare Implementation Science (2020–2022)

**Title:** “Early Fast-Track versus Standard Care for Persons with HIV Initiating Tenofovir Disoproxil Fumarate-Lamivudine-Dolutegravir in Haiti: A Pilot Randomized Trial”

**Amount:** \$507,738

**Principal Investigator:** Serena Koenig

**Co-Investigators:** Samuel Pierre, Jessy Devieux, Pierre Cremieux, and Daniel Ariely

**Funding source:** National Institute of Health (NIH/NIMH R34MH114739) (2018–2020)

**Title:** “Immediate Fast-Track versus Standard Care for Persons Living with HIV in Haiti: A Randomized Pilot Study”

**Amount:** \$530,457

**Principal Investigator:** Serena Koenig

**Co-Investigators:** Jessy Devieux, Heejung Bang, and Pierre Cremieux

**Funding source:** National Institute of Health (NIH/NIAID R01AI131998). (2017–2021)

**Title:** “A Trial of Same-Day Testing and Treatment to Improve Outcomes among Symptomatic Patients Newly Diagnosed with HIV”

**Amount:** \$1,658,285

**Principal Investigators:** Co-Principal Investigators Jack Maypole and Matthew Sadof

**Head of statistical evaluation team:** Pierre-Yves Cremieux

**Funding source:** Health Care Innovation Award from the Centers for Medicare and Medicaid Services (2015–2018)

**Title:** “Massachusetts Alliance for Complex Care.”

**Amount:** \$6,100,000

**Researchers:** Catherine Haeck, Pierre Lefebvre, Philip Merrigan, and Pierre-Yves Cremieux (Université du Québec à Montréal), and Nancy Mayo (McGill University)

**Funding source:** FRSQ (2013)

**Title:** “Analysis of the impact of public policies on population health and welfare”

**Amount:** \$145,000

**Researchers:** Pierre-Yves Cremieux and Catherine Garnier (Université du Québec à Montréal)

**Funding source:** Canadian government (2003–2008)

**Title:** “La chaîne du médicament” (The drug process)

**Amount:** \$2,500,000

**Researchers:** Pierre-Yves Cremieux, Pierre Ouellette, and Pierre Fortin (Université du Québec à Montréal)

**Funding source:** Quebec Ministry of Research, FCAR (2001–2004)

**Title:** “Performance hospitalière” (Hospital performance)

**Amount:** \$75,000

**Researchers:** Pierre-Yves Cremieux and Pierre Ouellette (Université du Québec à Montréal)

**Funding source:** Quebec Ministry of Health (1997)

**Title:** “Etude d’impact sur le projet de loi sur le tabac” (Analysis of the impact of a proposed legislation on tobacco)

**Amount:** \$75,000

#### **OTHER PROFESSIONAL ACTIVITIES**

- 2015 Guest editor, *PharmacoEconomics: Economic Consequences of Obesity*, with Christian Frois, Volume 33, Issue 7. New York, NY: Springer International Publishing (July 7, 2015)
- January 2013–December 2014 Lecturer, “International Antitrust,” M.B.A. course, Yale School of Management
- 2007–2012 Member, Drug Safety and Monitoring Board, Genta Inc.
- Spring 2007, Spring 2009 Lecturer, “Labor Economics,” Ph.D. course, Boston University
- 1999 External committee member, Ph.D. thesis, Madame Michele Savoie, *Une étude de Propension à payer pour la prévention du cancer du sein*, Département des sciences biomédicales, Faculté de Médecine. Jacques LeLorier and Pierre Ouellette, Co-advisors.
- 1996 Evaluation of the Masters Programs of the Centre des Techniques de Planification et d’Economie Appliquée in Haïti
- 1997 Member, Observation Mission for the *Concertation pour Haiti* on the privatization of state owned companies in Haiti

#### **CURRENT BOARD MEMBERSHIPS**

- 2018–Present Member of the Board of Directors, Partners in Health, Inc.
- 2016–Present Member of the Board of Directors, Boston Medical Center
- 2016–Present Member of the Board of Directors, The Haitian Group of the Study of Kaposi’s Sarcoma and Opportunistic Infections; GHESKIO USA
- 2015–Present Member of the Board of Directors, ALIMA, USA
- 2013–Present Member of the Board of Trustees, Partners in Health, Inc.